E Rostron1, M McKibbin. 1. Department of Ophthalmology, St James's University Hospital, Beckett Street, Leeds, W Yorkshire, UK.
Abstract
AIM: The aim of this study was to evaluate trends in visual impairment certification due to age-related macular degeneration (ARMD) in the Leeds metropolitan area between 2005 and 2010. METHODS: In this retrospective study, the primary causes of visual impairment certification in the Leeds metropolitan area between 2005 and 2010 were reviewed. ARMD was considered to be the cause of certification when recorded as the primary factor contributing to visual impairment in one or both eyes. The incidence of visual impairment certification due to ARMD was calculated using population estimates from the Office of National Statistics. RESULTS: ARMD was the primary cause of visual impairment certification in all study years, accounting for 58.7 and 50.8% of certifications in 2005 and 2010, respectively. For the same period, the incidence of certification due to ARMD fell from 364 to 248 per million population per year. This was largely the result of a fall in the incidence of visual impairment certification due to neovascular ARMD from 225 to 137 per million population per year, beginning in 2008 after the introduction of a local commissioning policy on the use of intra-vitreal ranibizumab. CONCLUSION: The incidence of visual impairment certification due to ARMD in the Leeds metropolitan area appears to be falling. This is largely the result of a decrease in certification secondary to neovascular ARMD. This represents a change in the previously described trend for ARMD visual impairment certification.
AIM: The aim of this study was to evaluate trends in visual impairment certification due to age-related macular degeneration (ARMD) in the Leeds metropolitan area between 2005 and 2010. METHODS: In this retrospective study, the primary causes of visual impairment certification in the Leeds metropolitan area between 2005 and 2010 were reviewed. ARMD was considered to be the cause of certification when recorded as the primary factor contributing to visual impairment in one or both eyes. The incidence of visual impairment certification due to ARMD was calculated using population estimates from the Office of National Statistics. RESULTS: ARMD was the primary cause of visual impairment certification in all study years, accounting for 58.7 and 50.8% of certifications in 2005 and 2010, respectively. For the same period, the incidence of certification due to ARMD fell from 364 to 248 per million population per year. This was largely the result of a fall in the incidence of visual impairment certification due to neovascular ARMD from 225 to 137 per million population per year, beginning in 2008 after the introduction of a local commissioning policy on the use of intra-vitreal ranibizumab. CONCLUSION: The incidence of visual impairment certification due to ARMD in the Leeds metropolitan area appears to be falling. This is largely the result of a decrease in certification secondary to neovascular ARMD. This represents a change in the previously described trend for ARMD visual impairment certification.
Authors: Philip J Rosenfeld; Howard Shapiro; Lisa Tuomi; Mary Webster; Julee Elledge; Barbara Blodi Journal: Ophthalmology Date: 2011-03 Impact factor: 12.079
Authors: R Robinson; J Deutsch; H S Jones; S Youngson-Reilly; D M Hamlin; L Dhurjon; A R Fielder Journal: Br J Ophthalmol Date: 1994-10 Impact factor: 4.638
Authors: P Mitchell; J-F Korobelnik; P Lanzetta; F G Holz; C Prünte; U Schmidt-Erfurth; Y Tano; S Wolf Journal: Br J Ophthalmol Date: 2009-05-13 Impact factor: 4.638
Authors: A C Bird; N M Bressler; S B Bressler; I H Chisholm; G Coscas; M D Davis; P T de Jong; C C Klaver; B E Klein; R Klein Journal: Surv Ophthalmol Date: 1995 Mar-Apr Impact factor: 6.048
Authors: M Buckle; A Lee; Q Mohamed; E Fletcher; A Sallam; R Healy; I Stratton; A Tufail; R L Johnston Journal: Eye (Lond) Date: 2015-01-16 Impact factor: 3.775
Authors: W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang Journal: Eye (Lond) Date: 2015-04-17 Impact factor: 3.775
Authors: Monica M Michelotti; Salwa Abugreen; Simon P Kelly; Jiten Morarji; Debra Myerscough; Tina Boddie; Ann Haughton; Natalie Nixon; Brenda Mason; Evangelos Sioras Journal: Clin Ophthalmol Date: 2014-04-15
Authors: Eric H Souied; Pravin U Dugel; Alberto Ferreira; Ron Hashmonay; Jingsong Lu; Simon P Kelly Journal: Ophthalmic Epidemiol Date: 2016-02-08 Impact factor: 1.648
Authors: Robert P Finger; Vincent Daien; Bora M Eldem; James S Talks; Jean-Francois Korobelnik; Paul Mitchell; Taiji Sakamoto; Tien Yin Wong; Krystallia Pantiri; Joao Carrasco Journal: BMC Ophthalmol Date: 2020-07-17 Impact factor: 2.209
Authors: Holly D H Brown; Rachel L Woodall; Rebecca E Kitching; Heidi A Baseler; Antony B Morland Journal: Ophthalmic Physiol Opt Date: 2016-05 Impact factor: 3.117